Advanced Research Center, Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$101,579	10
2024	Research	$612,795	15
2023	Research	$701,828	11
2022	Research	$71,363	18
2021	Research	$67,635	5
2020	Research	$57,426	9

Breakdown

Who paid Research payments · program years 2020–2025

Novavax Inc $1,416,202 36 payments
Anika Therapeutics, Inc. $110,985 9 payments
Avanir Pharmaceuticals, Inc. $85,439 23 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age $701,828 11 payments
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years $612,795 15 payments
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $110,985 9 payments
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age $101,579 10 payments
18-Avp-786-207 $72,139 15 payments
20-Avp-786-307 $13,300 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.